

# Fostair® (beclometasone/formoterol) Asthma Search Tool Rationale

This document explains the search rationale used to identify adult patients with asthma potentially eligible for Fostair®.

**This promotional search tool has been fully funded by Chiesi Ltd and developed by Oberoi Consulting Ltd.**

Chiesi is providing this search tool to support clinicians in identifying adult asthma patients potentially eligible for Fostair® (beclometasone/formoterol) [BDP/FF]. The search tool does not replace clinical judgement. Chiesi recommends that all patients are reviewed to determine whether further investigations are required prior to optimising pharmacological therapies or changing non-pharmacological interventions. This enables the healthcare professional to make an informed decision regarding the most appropriate intervention, in collaboration with the patient. It is the responsibility of the healthcare organisation to access the list of patients generated by the searches and to clinically review the patients identified. Please note that Fostair® may not be appropriate for all patients identified by this tool. Patient cohorts have been broken down by severe exacerbations (oral corticosteroid issues as a surrogate marker) and/or SABA to indicate current symptom burden and potential future risk of exacerbations. This approach supports the identification of patients who may have a higher-risk disease profile. Please note Fostair® is indicated for the maintenance treatment of asthma in adults where use of a combination product is appropriate (please see full licensed indication).

## Fostair® Licensing Information

**Fostair® 100/6 (pMDI and NEXThaler) and 200/6 (pMDI and NEXThaler) are indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:**

- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or
- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

**Fostair® pMDI 100/6 and Fostair® NEXThaler 100/6 are licensed for maintenance and reliever therapy (MART). Fostair® MART (100/6 only) should especially be considered for adult patients with:**

- not fully controlled asthma and in need of reliever medication
- asthma exacerbations in the past requiring medical intervention

**Fostair® Prescribing Information can be found here:** <https://www.chiesiasthma.co.uk/hcp/prescribing-information-2/#fostair>

**Clenil® (beclometasone) Prescribing information can be found here:** <https://www.chiesiasthma.co.uk/hcp/prescribing-information-2/#clenil>



**Adverse events** should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or [PV.UK@Chiesi.com](mailto:PV.UK@Chiesi.com).

# Patient Cohorts

## Identification focus:

Patients on ICS-only preventer may have suboptimal asthma control and be relying heavily on SABA and/or having exacerbations.<sup>1-3</sup>


## Clinical opportunity:

Assessment for potential step-up to an appropriate regimen such as Fostair® where appropriate.

## Rationale:

Help optimise symptom control, appropriately manage SABA use and exacerbation risk, align with evidence-based asthma management pathways, and simplify treatment where possible<sup>4</sup>

### Parent population: adult asthma patients on ICS\* only



**Prioritised by severity of exacerbations, followed by high symptom burden. Patients in each group excluded from subsequent cohorts.**

ICS: inhaled corticosteroid; SABA: short-acting  $\beta_2$  agonist; OCS: oral corticosteroid

\*Prescription issued within last 4 months \*\*Prescription issued within last 12 months

1. National Institute for Health and Care Excellence, British Thoracic Society & Scottish Intercollegiate Guidelines Network (2024). Asthma: diagnosis, monitoring and chronic asthma management. NICE Guideline NG245. London: NICE. Published 27 November 2024. ISBN-13: 978-1-4731-6612-7. [Last Accessed April 2026]. 2. Global Initiative for Asthma (2025). Global Strategy for Asthma Management and Prevention. Updated May 2025. Global Initiative for Asthma. Available at: <https://ginasthma.org> [Last Accessed April 2026]. 3. Levy, M., Andrews, R., Buckingham, R., Evans, H., Francis, C., Houston, R., Lowe, D., Nasser, S., Paton, J., Puri, N., Stewart, K. & Thomas, M. (2014). Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London: Royal College of Physicians. Available at: <https://www.rcp.ac.uk/media/i2jkbmc/why-asthma-still-kills-full-report.pdf> [Last Accessed: April 2026]. 4. Papi et al., 2013, Eur Respir J, 41:1384-1392. Available at: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(13\)70012-2/abstract](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70012-2/abstract) [Last accessed: April 2026].

## Exclusion Criteria

- Patients on the palliative care register (red or amber) are excluded
- Patients prescribed Fostair® (beclometasone/formoterol) within the last 4 months
- Patients prescribed any inhaler containing a LABA or LAMA (regardless of whether they are single drug inhalers or combination inhalers) within the last 4 months

## ICS Only Inhalers Included in the Searches

A comprehensive list of all currently marketed inhalers that are included in the searches are listed below, this list has been verified using NICE/BTS/SIGN and Rightbreathe.<sup>1,2</sup>

Inhalers are selected by both brand and generic name.

### Beclometasone

Easyhaler Beclometasone 200mcg (DPI)  
Clenil Modulite (Beclometasone) 200mcg (pMDI)  
Soprobec 200mcg (pMDI)  
Clenil Modulite (Beclometasone) 250mcg (pMDI)  
Kelhale 100mcg (pMDI)  
Soprobec 250mcg (pMDI)  
Qvar 100mcg Autohaler (pMDI)  
Qvar 100mcg Easi-Breathe (pMDI)  
Qvar 100mcg (pMDI)

### Budesonide

Easyhaler Budesonide 200mcg (DPI)  
Pulmicort 200mcg Turbohaler (DPI)  
Budelin Novolizer 200mcg (DPI) + refill  
Budesonide Easyhaler 400mcg (DPI)  
Pulmicort 400mcg Turbohaler (DPI)  
Pulmicort 0.5mg and 1mg Respules

### Ciclesonide

Alvesco 80mcg (pMDI)  
Alvesco 160mcg (pMDI, 60 doses, 120 doses)

### Fluticasone

Flixotide 125mcg Evohaler (pMDI)  
Flixotide 250mcg Accuhaler (DPI)  
Flixotide 250mcg Evohaler (pMDI)  
Flixotide 500mcg Accuhaler (DPI)

### Mometasone

Asmanex 200mcg Twisthaler (DPI)  
Asmanex 400mcg Twisthaler (DPI)

ICS: inhaled corticosteroid; NICE: National Institute for Health and Care Excellence; BTS: British Thoracic Society; SIGN: Scottish Intercollegiate Guidelines; DPI: dry powder inhaler; mcg: micrograms; pMDI: pressurised, metered-dose inhaler.

1. National Institute for Health and Care Excellence, British Thoracic Society & Scottish Intercollegiate Guidelines Network, 2025. *Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline*, 12 November 2025.

Available at: <https://www.nice.org.uk/guidance/ng245/resources/inhaled-corticosteroid-doses-for-the-bts-nice-and-sign-asthma-guideline-pdf-13558148029> [Last Accessed: April 2026].

2. RightBreathe. Available at: <https://www.rightbreathe.com> [Last Accessed: April 2026].

## SABA Inhalers Included in the Searches

The SABA reliever inhalers listed below are included in the searches, if issued in the last 12 months.

### Salbutamol

Airomir 100mcg Autohaler (pMDI)  
Airomir 100mcg Inhaler (pMDI)  
Easyhaler 100mcg (DPI)  
Easyhaler 200mcg (DPI)  
Salamol 100mcg Easi-Breathe inhaler (pMDI)  
Salamol 100mcg inhaler (pMDI)  
Salbulin Novolizer 100mcg (DPI)  
Ventolin 100mcg Evohaler (pMDI)  
Ventolin 200mcg Accuhaler (DPI)

### Terbutaline

Bricanyl 500mcg Turbohaler (DPI)

# Oral Corticosteroids

The oral corticosteroids listed below are included in the searches, if issued in the last 12 months.

## Oral Corticosteroids

- Prednisolone
- Prednisone
- Dexamethasone

# Key Differences in Search Construction

When building inhaler searches across clinical systems, the methodology differs due to how each system structures medication data.

## EMIS Web

- The searches are built to identify only active prescription status
- Only prescriptions that are both active and issued within the last 4 months are included
- Counts the actual number of inhalers issued.
  - Example: If 2 salbutamol inhalers are issued on one prescription, it counts as 2 inhalers.

## SystemOne

- The searches are built using issue date
- Inhalers issued within the last 4 months will be included even if discontinued
- Counts the number of prescriptions issued, not the number of inhalers.
  - Example: If 2 inhalers are on one prescription and this is issued 6 times in a year, it will show 6 issues, even though the patient received 12 inhalers.
- SystemOne searches may occasionally underestimate inhaler use because they do not count the total number of inhalers supplied.